RPL22P8

Across TCGA pan-cancer cohorts, RPL22P8 RNA is linked to patient survival in 20 of 34 cancer types, making it the most broadly survival-associated RPL22P8 data layer.

The strongest signal is observed in mesothelioma (MESO), where higher RPL22P8 RNA is associated with worse disease-free survival. In most high-consensus cancer types, elevated RPL22P8 expression acts as an unfavorable survival marker, although some lineages such as BLCA and SKCM show a favorable association.

MESO, ACC, and BLCA are the cancer types where RPL22P8 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
MESO	DFS	Median	All	0.277	0.453	.004	63	view →
ACC	OS	Tertile	All	0.229	0.874	<.001	48	view →
BLCA	DFS	Tertile	III,IV	0.700	0.401	.004	40	view →
SKCM	OS	Tertile	III,IV	0.884	0.618	.005	36	view →
THYM	DFS	Median	All	0.965	0.841	.004	17	view →
COAD	DFS	Quartile	All	0.742	0.491	.009	10	view →
CESC	DFS	Median	All	0.871	0.776	.016	10	view →
PAAD	DFS	Tertile	III,IV	0.152	0.821	.045	9	view →
KIRP	DFS	Quartile	II,III,IV	0.925	0.494	.027	6	view →
TGCT	DFS	Tertile	All	0.893	0.743	.038	6	view →
LUSC	OS	Quartile	II,III,IV	0.569	0.333	.014	5	view →
THCA	DFS	Quartile	IV	0.544	1.000	<.001	4	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 20 lineages.

RPL22P8–MESO (DFS)

Open the MESO breakdown →